Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Managing tardive dyskinesia.

D E Casey

    The Journal of Clinical Psychiatry
    |October 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Early recognition and systematic treatment are crucial for managing tardive dyskinesia, a delayed side effect of neuroleptic drugs. This guide outlines management strategies, drug treatments, and recent developments for tardive dyskinesia.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy.

    International journal of clinical practice·2014
    Same author

    Antipsychotic drugs dose-dependently suppress the spontaneous hyperactivity of the chakragati mouse.

    Neuroscience·2010
    Same author

    Antipsychotic drug-induced weight gain: development of an animal model.

    International journal of obesity (2005)·2005
    Same author

    The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates.

    Psychopharmacology·2001
    Same author

    Effects of benztropine on ketamine-induced behaviors in Cebus monkeys.

    Behavioural pharmacology·2001
    Same author

    Clinical trial design issues in schizophrenic research.

    The Journal of clinical psychiatry·2001
    Same journal

    Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

    The Journal of clinical psychiatry·2026
    Same journal

    Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

    The Journal of clinical psychiatry·2026
    Same journal

    Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

    The Journal of clinical psychiatry·2026
    Same journal

    Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

    The Journal of clinical psychiatry·2026
    Same journal

    Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

    The Journal of clinical psychiatry·2026
    Same journal

    The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

    The Journal of clinical psychiatry·2026
    See all related articles

    Area of Science:

    • Neuroscience
    • Pharmacology
    • Clinical Medicine

    Background:

    • Tardive dyskinesia (TD) is a significant, delayed adverse effect associated with long-term neuroleptic medication.
    • Early identification of TD is essential for effective patient management and preventing progression.
    • Current treatment approaches for TD require systematic planning and updated therapeutic strategies.

    Purpose of the Study:

    • To provide a structured outline for the management of tardive dyskinesia.
    • To detail effective drug treatments and therapeutic strategies for TD.
    • To summarize recent advancements in the understanding and treatment of tardive dyskinesia.

    Main Methods:

    • Literature review of recent developments in tardive dyskinesia.
    • Development of a systematic management guideline.

    Related Experiment Videos

  • Compilation of current drug treatment options.

    • Main Results:

    • An actionable outline for recognizing and managing tardive dyskinesia has been established.
    • Key drug treatments and management strategies are summarized.
    • Recent therapeutic developments are highlighted.

    Conclusions:

    • A systematic approach to management, incorporating early recognition and updated treatment protocols, is vital for addressing tardive dyskinesia.
    • Clinicians can utilize this outline for improved patient care regarding neuroleptic-induced movement disorders.
    • Ongoing research and development continue to offer new therapeutic avenues for tardive dyskinesia.